Keep track of advancements in every frontier
Isomorphic Labs—Drug design engine and pipelineIsomorphic Labs—
AlphaFold 3
Courtesy of Isomorphic Labs / Google DeepMind · Press kit, editorial use (opens isomorphiclabs.com)

AlphaFold 3

by Isomorphic LabsGB

ScalingStage 5 of 5

Free via AlphaFold Server and as research code; used in-house for drug design.

Updated 9 Oct 2024Checked 25 Sep0 updates this week

Milestones

No announced next step
  1. Published in Nature; free AlphaFold Server8 May 2024Complete.
  2. Code released for researchersNov 2024Complete.

Most important updates

  • 9 Oct 2024
  • 8 May 2024

Physics limits

  • Too little good data about how drugs bindOnly about 230,000 molecular structures have been solved by experiment, and far fewer have reliable binding measurements. Models trained on that are weakest on exactly the novel chemistry drugmakers want.
  • It predicts one snapshot, not motionProteins flex, open and close. The model gives a single likely shape, and struggles with floppy regions and with how structures change when a drug binds.
  • Confident shapes can still be wrongTrained to produce plausible structures, it can place atoms convincingly where no real structure exists, especially for new kinds of molecules unlike its training data.

How it works

3 parts
Protein crystals under the microscope: X-ray structures of crystals like these are the data AlphaFold learned 3D shapes from
Protein crystals under the microscope: X-ray structures of crystals like these are the data AlphaFold learned 3D shapes fromPhoto: CSIRO · CC BY 3.0 (opens commons.wikimedia.org)
Input

Just the sequences

You give it the sequences of proteins, DNA or RNA, plus any small molecules or metal ions that bind them.

Reason

Learn which parts touch

A network compares every pair of building blocks to infer which lie close together in 3D, learned from solved structures.

Build

Generate the 3D shape

A diffusion model, like those in image AI, turns random noise step by step into atom positions for the whole complex.

Papers & demos

2 items
  1. Nov 2024code
    AlphaFold 3 code and weights released for academic use (opens github.com)Let outside scientists test it, after criticism of the first web-only release.
  2. 8 May 2024paper

Update log

2 updates

Wed 9 Oct 2024

  • Major: PressResearch

Wed 8 May 2024

  • Major: PaperResearch

About Isomorphic Labs

The team behind AlphaFold 3

Isomorphic Labs

AI drug design, AlphaFold 3

Alphabet company spun out of Google DeepMind in 2021, led by Demis Hassabis. It co-built AlphaFold 3, which predicts how proteins, DNA and drugs fit together, and uses it to design drugs with Lilly, Novartis and for itself. First trials expected by end of 2026.

  • Raised its first outside money, $600M led by Thrive Capital, in Mar 2025, then a reported $2.1B in May 2026.
  • The goal of AI-designed drugs in trials by end of 2025 slipped; now expected by end of 2026.
  • Its Lilly and Novartis deals (Jan 2024) could pay up to about $3B if goals are hit.
Founded
20215 yrs
Headquarters
United Kingdom
Status
Subsidiaryof Alphabet
Valuation
Alphabet-owned
Raised
$2.7B2 rounds
Last round
Series B · $2.1BMay 2026
Works in
BiotechAI drug discoveryAI
Coverage
2 programs · 7 updateslatest 1 May 2026checked 25 Sep
Lead investors
Thrive Capital
Primer